Barriers to HIV care in Uganda and implications for universal test-and-treat: a qualitative study.


Journal

AIDS care
ISSN: 1360-0451
Titre abrégé: AIDS Care
Pays: England
ID NLM: 8915313

Informations de publication

Date de publication:
05 2022
Historique:
pubmed: 28 7 2021
medline: 14 5 2022
entrez: 27 7 2021
Statut: ppublish

Résumé

Achieving universal HIV test-and-treat will require targeted interventions for those with worse outcomes, including advanced HIV. We conducted qualitative, semi-structured interviews with healthcare workers (HCWs) and people living with HIV (PLWH) at 5 HIV clinics in Kampala, Uganda, to understand barriers to care. PLWH enrolled started/restarted on HIV treatment ≤3 months prior. PLWH were grouped as 1) "ART-experienced" or those restarted therapy after ≥12 months off, 2) ART naïve CD4 count <100 cells/uL "late presenters" or 3) ART naïve CD4 count >350 cells/uL "early presenters". In-depth interviews were conducted in Luganda, translated, and transcribed verbatim. Between May and August 2017, 58 PLWH and 20 HCWs were interviewed. High stigma and low social support emerged as themes among all as barriers to care. Alcohol abuse was a barrier for men. Fear of domestic violence and abandonment were barriers for women, limiting disclosure of their HIV status to their male partners. Clinic factors such as rapport with staff, distance, efficiency, and privacy impacted care. Future interventions to decrease delayed ART initiation should target stigma and social support. Assisted disclosure, contact tracing, and alcohol abuse treatment should be implemented. Strengthening client support, reducing wait times, and increasing privacy assurances would improve care-seeking behaviors.

Identifiants

pubmed: 34314261
doi: 10.1080/09540121.2021.1946000
pmc: PMC8792098
mid: NIHMS1718871
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

597-605

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS086312
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002494
Pays : United States
Organisme : NIMH NIH HHS
ID : K23 MH121220
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI055433
Pays : United States
Organisme : FIC NIH HHS
ID : R25 TW009345
Pays : United States

Références

PLoS One. 2018 Aug 30;13(8):e0202990
pubmed: 30161172
HIV Med. 2004 Mar;5(2):93-8
pubmed: 15012648
AIDS Res Ther. 2015 Dec 02;12:40
pubmed: 26633988
Curr HIV Res. 2011 Sep;9(6):429-45
pubmed: 21999778
SAHARA J. 2015;12:76-86
pubmed: 26711063
AIDS. 1995;9 Suppl A:S251-7
pubmed: 8819593
J Int Assoc Provid AIDS Care. 2016 Nov;15(6):505-511
pubmed: 25589304
S Afr Med J. 2017 Nov 27;107(12):1058-1064
pubmed: 29262956
Sex Transm Infect. 2015 Dec;91(8):615-20
pubmed: 26056389
AIDS Res Ther. 2011 Feb 28;8:8
pubmed: 21356115
Sex Transm Infect. 2017 Jul;93(Suppl 3):
pubmed: 28736395
N Engl J Med. 2015 Aug 27;373(9):808-22
pubmed: 26193126
AIDS Behav. 2020 Feb;24(2):357-362
pubmed: 31907675
PLoS Med. 2009 Jan 27;6(1):e11
pubmed: 19175285
BMC Public Health. 2016 May 03;16:369
pubmed: 27142869
BMC Infect Dis. 2018 Jul 3;18(1):298
pubmed: 29970017
Lancet. 2009 Jan 3;373(9657):48-57
pubmed: 19038438
AIDS Res Treat. 2012;2012:817506
pubmed: 22400106
BMC Infect Dis. 2019 Jun 17;19(1):534
pubmed: 31208360
PLoS One. 2019 Feb 13;14(2):e0211619
pubmed: 30759138
PLoS Med. 2013;10(1):e1001369; discussion e1001369
pubmed: 23341753
J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):280-9
pubmed: 19521248
Lancet. 2015 Jul 11;386(9989):123-4
pubmed: 26159391
Ann Intern Med. 2011 Aug 16;155(4):209-16
pubmed: 21768555
AIDS Behav. 2018 Dec;22(12):3815-3825
pubmed: 29453552
BMC Public Health. 2019 Aug 27;19(1):1172
pubmed: 31455306
J Int AIDS Soc. 2017 Dec;20(4):
pubmed: 29251433
Nurs Res Pract. 2016;2016:5172497
pubmed: 28116154
PLoS One. 2018 Aug 16;13(8):e0201644
pubmed: 30114244
J Int AIDS Soc. 2018 Oct;21(10):e25198
pubmed: 30362662

Auteurs

Sarah M Lofgren (SM)

University of Minnesota, Division of Infectious Diseases and International Medicine, Department of Medicine, Minneapolis, MN, USA.
Infectious Diseases Institute, Makerere University, Kampala, Uganda.

Sharon Tsui (S)

Infectious Diseases Institute, Makerere University, Kampala, Uganda.

Lynn Atuyambe (L)

Makerere University, School of Public Health, Kampala, Uganda.

Leander Ankunda (L)

Makerere University, School of Public Health, Kampala, Uganda.

Robina Komuhendo (R)

Makerere University, School of Public Health, Kampala, Uganda.

Nathan Wamala (N)

Makerere University, School of Public Health, Kampala, Uganda.

Alisat Sadiq (A)

Infectious Diseases Institute, Makerere University, Kampala, Uganda.

Paul Kirumira (P)

Infectious Diseases Institute, Makerere University, Kampala, Uganda.

Diksha Srishyla (D)

University of Minnesota, School of Public Health, Minneapolis, MN, USA.

Andrew Flynn (A)

Infectious Diseases Institute, Makerere University, Kampala, Uganda.

Katelyn A Pastick (KA)

Infectious Diseases Institute, Makerere University, Kampala, Uganda.
University of Minnesota, School of Medicine, Minneapolis, MN, USA.

David B Meya (DB)

Infectious Diseases Institute, Makerere University, Kampala, Uganda.

Noeline Nakasujja (N)

Infectious Diseases Institute, Makerere University, Kampala, Uganda.
Makerere University, Department of Psychiatry, Kampala, Uganda.

Carolyn Porta (C)

University of Minnesota, School of Public Health, Minneapolis, MN, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH